Osteoporosis is a major health problem affecting both men and women. statins, besides their action as lipid-lowering agents, seem to have additional pleiotropic properties, among them a beneficial effect on bone mineral density. the entirety of experimental and the majority of clinical studies as well as the only relevant meta-analysis suggest that statins have an anabolic effect on bone metabolism. statins, osteoporosis and adipogenesis share the same pathway, rANKL/OPG. It would appear that an imbalance in this pathway could be responsible for the manifestation of some metabolic disorders such as diabetes mellitus, atherogenesis, multiple myeloma, osteoporosis. Possibly in the future, drugs which can intervene in this biochemical and pathophysiological cascade, like statins, in a variety of doses, could be used for the management of ectopic ossification syndromes and other bone disorders, even as an additive treatment. Until then, further large longitudinal randomized controlled studies for each statin separately are required to confirm this hypothesis.
INTRODUCTION
Osteoporosis is a serious health problem not only because it affects the quality of life but also and more importantly because it is associated with morbidity and mortality as well as economic burden. According to the WHO, osteoporosis is a "systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue which leads to bone fragility and susceptibility to fracture". Bone mineral density (BMD) in osteoporotic patients is less than -2.5 SD compared with the BMD of young people (T-score<-2.5 SD). BMD of people without osteoporosis is usually above -1SD. 1 Osteoporosis is a more frequent disease in women than in men, 2 although mortality due to osteoporotic fractures is higher in men than in women. 3 In addition to this, post-menopausal women suffer from osteoporosis and osteoporotic fractures at a higher frequency than pre-menopausal women. 4 Through adult life there is a dynamic progress which is called "bone remodeling". Bone remodeling is well established throughout the literature and involves both systemic and non-systemic factors. 5 It is well known that in this procedure an important role is played by the system of receptor activator of nuclear factor kappa b ligand (RANKL)-osteoprotegerin (OPG), 6 some cytokines and bone morphogenetic proteins (BMPs) (Figure 1 ). 7 On the other hand, it has been well known since the 70s that bone loss in osteoporotic patients is associated with increase of adipose tissue in bone marrow. 8 Mesenchymal stem cells are pluripotent cells with a high mitotic index and are involved in the differentiation of adipocytes under the regulation of genes and transcription factors. Adipose tissue is considered as a separate endocrine gland, responsible for the secretion of adipokines (leptin, adiponectin) and hormones (vitamin D3, estrogen, etc.) and is involved in the pathophysiology of some entities. Leptin controls the RANKL/OPG axis by inhibiting the expression of RANKL and inducing OPG to create pre-osteoblasts and mononuclear cells in circulation. The diversion of an adipocyte into osteoblast is considered to be a multifactorial process regulated by all these factors ( Figure 2 ). In addition to this, it is well known that statins, osteoporosis and adipogenesis share the same pathway, RANKL/OPG. 9, 10 It appears that an imbalance in this pathway could be responsible for the manifestation of some metabolic disorders such as diabetes mellitus, Figure 1 . Bone metabolism enhanced by growth factors like bone morphogenetic proteins (BMPs), transforming growth factors beta (TGF-β), insulin growth factors (IGFs), fibroblast growth factors (FGFs). Systemic factors can also enhance osteoblast differentiation and proliferation. Systemic factors and locally produced growth factors can also induce activation of osteoclasts. Interleukins, prostaglandins and M-CSF produced from osteoblasts also induce the formation of osteoclasts. RANKL binds its receptor RANKL and induces the formation of osteoclasts. OPG inhibits RANKL binding to RANK.
CURReNT maNagemeNT Of OsTeOpOROsIs
It is now generally accepted that first-line agents for the management of osteoporosis are the aminobiphosphonates. These drugs act to decrease bone resorption by inhibition of the farnesyl diphosphate synthase, which is a step in the mevalonic acid pathway. 12 3-Hydroxy-3-Methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) inhibit the same pathway at an earlier point and may also antagonize osteoclasts by increasing expression of osteoprotegerin ( Figure 3) . 13 In order to improve BMD and prevent osteoporosis, we have used many different drugs based on two treatment strategies: i) to inhibit the osteoclast activity and ii) to stimulate the osteoblast activity. First-line agents to avoid bone resorption are the biphosphonates like alendronate, risedronate, ibandronate and zoledronic acid. 14, 15 Other drugs used are teriparatide, a recombinant form of parathyroid hormone, 16 selective estrogen receptor modulators (SERMs), hormone replacement therapy, calcitonin, calcitriol and vitamin D analogues. [17] [18] [19] We also have agents with a different atherogenesis, multiple myeloma, osteoporosis. We have also seen that fat and bone tissue interaction altered by activation or silencing of genes, signaling molecules and transcription factors.
11
The purpose of our review is to investigate whether, according to the available clinical data, there is a relation between statins and osteoporosis and thus to pose queries regarding new pathways which may enhance our knowledge about the prevention and management of osteoporosis. Clinical studies, systematic reviews and meta-analyses were searched for in PUBMED and EMBASE/EXCERPTA MEDICA databases. Computerized search of the databases was accomplished by using the combination of keywords and Medical Subject Heading terms such as: statins, aminobiphosphonates, osteoporosis, RANKL, OPG, BMP, HMG-CoA reductase inhibitors, BMD, adipose tissue. We limited our search to articles published between June 2007 and October 2011 that were at least accompanied by an English abstract. We have found that there is a meta-analysis including all the clinical studies until June 2007. 
Lipid-lowering therapy and pleiotropic effects
Statins compose a drug class broadly characterized as lipid-lowering agents. 21 These agents can be subgrouped according to their hydrophobic or hydrophilic nature. Hydrophobic statins (simvastatin, lovastatin) enter the liver by the hepatic portal vein, while the hydrophilic statins (rosuvastatin, pravastatin, fluvastatin) require active transport into the cell. 22 Statins inhibit mevalonic acid synthesis and, as a consequence, there is a decrease in the amount of total cholesterol and decreased levels of low density lipoproteins (LDL). 23 All statins have favorable effects on cardiovascular diseases, the nervous system, the immune system, the skeletal system, tumor growth. 24, 25 There is emerging interest in the pleiotropic effects of this class of drugs, e.g. Srivastava and colleagues 26 who examined the possible action of atorvastatin in acute phase reaction in children after intravenous biphosphonate infusion, but who, however, failed to demonstrate a positive result.
Statins and bones: metabolism and clinical implications
Molecular biology and genetics reveal that both vascular and osteoblast biology have a common pathway: RANK/RANKL/OPG. [27] [28] [29] With regard to this issue, there is growing interest concerning the possible mechanism and the impact of statins on bones on either the experimental or the clinical level. Mundy and colleagues in 1999 were the first to report an anabolic effect of statins in cultured mouse and human bone cells. Both simvastatin and lovastatin enhanced the expression of bone morphogenetic protein-2 (BMP-2) mRNA. 30 
Experimental studies
Several experimental studies illustrate the effect of statins in bone metabolism either in vitro or in vivo. 51 demonstrated controversial, and even negative, effects of statins on bone repair, the vast majority of the studies in Table 1 support the beneficial role of this group of drugs. The administration of statins presents anabolic effects by promoting osteoblast activity and suppressing osteoclasts. As a result, statins act effectively on bone formation, inhibition of BMD decrease and, in general, on fracture healing and osteoporosis prevention. However, we should take into account that these studies refer to different animal models, they used different doses and the result was a local phenomenon, beyond the established cholesterol-lowering effect of statins. Nevertheless, certain studies underline the remarkable increase of relevant growth factors (TGFβ-1, VGF), revealing a possible explanation for the statins and bones interaction.
Further studies performed in vitro, in cell cultures (Table 2) , support the previous findings, thus clarifying the potential mechanism of the beneficial effect of statins on bone metabolism. The expression of genes as BMP-2, COLLIA1, osteocalcin (OC) (which demonstrate an anabolic effect) and depression of others like RANKL (leading to suppression of osteoclast activity), all stimulated by statins, may regulate the role of this class of drugs in bone formation. Hughes A et al in 2007 52 found that hydrophobic and hydrophylic statins can inhibit osteoclast function in vitro, thereby showing a possible class effect, although stronger evidence supports the role of lipophilic agents as simvastatin (Pagkalos et al 60 ).
Observational studies
An interesting meta-analysis of clinical studies since 2007 by Uzzan et al 61 showed that statins have a positive effect on BMD in various sites. In particular, the better effect on BMD was found by lipophylic statins (simvastatin, lovastatin). The authors proposed that statins could be used for the management of osteoporosis, but the minimum concentration required for the beneficial effects on bone remains to be determined.
Several clinical studies since then have demonstrated the positive effect of statins on bones. Table 3 displays the main characteristics of these studies and their effect on BMD and bone biochemical markers. All these studies found a significant change either in BMD or in bone markers, except for three studies which found no statistically significant correlation.
Among these studies, there are four controlled studies, one cross-sectional, three open-label, one open randomized and one cohort study. Although not all of them are characterized by a strictly controlled study design, the vast majority reveal a positive effect on BMD and bone biochemical markers. Furthermore, as shown in Table 1 the controlled studies, even though not establishing the effects on BMD, showed significant changes in bone markers, which corroborates the hypothesis of the correlation between statins and bone formation.
DIsCUssION
The pleiotropic effect of statins has led clinicians to investigate their potential use among other entities, such as bone metabolism. Uzzan et al, 61 in their aforementioned meta-analysis, found that statins have a positive effect on BMD in various sites. Although the authors concluded that there was a modest but statistically significant favorable effect of statins on BMD, thus confirming the results of previous studies, we are as yet far from an evidence-based recommendation of statins as a useful therapeutic modality in osteoporotic patients, even as a complementary one. In addition, more data are needed to support the use of statins for prevention of bone fracture. This perception has mainly been developed by experimental studies, there being a lack of observational studies to clarify the field. The majority of the literature showed an increase in BMD or in bone markers. Several reasons might be advocated to explain the discrepancies. In fact, the doses used in experimental models which provided a favorable effect were much higher than the doses used in clinical practice. In addition, implementation of treatment was in a short-term perspective. Although obesity and physical activity were associated with prevention of fracture risk, they were neither controlled nor quantified. Thus, the control groups in most of the studies were small, thereby not reflecting an equal, comparative population and thus leading to bias.
On the other hand, statins could be prescribed in people with lower risk for fractures. Moreover, most of the studies attribute the interaction of statins with bone metabolism to a class-effect mechanism rather than to an individual drug effect. We have to stress here that we do not have extensive data on the pharmacological effects of statins in nonhypercholesterolemic patients.
All the available data from the literature, including evidence from experimental studies as well as from the vast majority of observational studies and the results of a single meta-analysis, suggested that there is a positive effect of statins on BMD, although another meta-analysis by Bauer et al 72 showed evidence that the beneficial effects on BMD and on fracture risk are observational, while many limitations and the placebo-controlled trials did not demonstrate any clear-cut benefit. However, the in vitro and some clinical studies (Chuengsamarn et al 71 ) suggest that statins inhibit bone resorption and stimulate bone formation, having a dual action on bone metabolism. Therefore, in the future statins might gain a position among drugs used for the prevention and management of osteoporosis, taking into account that clinicians already have a good deal of experience in prescribing statins, for other indications, and feel familiar with this drug family. Their anabolic and anti-resorptive effects on bone make them an ideal candidate for osteoporosis treatment.
In conclusion, statins, osteoporosis and adipogenesis share a major pathway, that of RANKL/RANK/ OPG. Moreover, fat and bone tissue interaction is altered by activation or silencing of genes signaling molecules and transcription factors. Possibly in the future drugs which intervene in this biochemical and pathophysiological cascade, like statins, in a variety of doses, could be used for the management of ectopic ossification syndromes and other bone disorders like osteoporosis and multiple myeloma, even as an adjuvant therapy. Until then, further large longitudinal randomized controlled studies for each statin separately are required to confirm this hypothesis.
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